Drug to Treat Parkinson’s Disease Launched in the US Market by Dr Reddy's Laboratories

Generic Pramipexole dihydrochloride extended-release tablets for treatment of Parkinson's disease has been launched by Dr Reddy's Laboratories in the US market.

It has launched the tablets in the strengths of 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg in the US market following approval from the US Food & Drug Administration (USFDA), said Dr Reddy's Laboratories.

Dr Reddy�s Laboratories Launch Tablets For Treatment Of Dementia In The US Market
Memantine hydrochloride tablets in the strengths of 5 mg and 10 mg are launched after getting the approval from the US Food and Drug Administration.

The company's product is generic version of Mirapex ER tablets. "The Mirapex ER brand and generic had US sales of approximately USD 48.3 million MAT for the most recent twelve months ending in June 2015 according to IMS Health," it said.

The DRL product is available in bottle count sizes of 30, it added.

Source-PTI

Chest Pain Drug Withdrawn by Dr. Reddy�s Laboratories From US Market
Dr Reddy's volunteered to withdraw 13,560 bottles of metoprolol succinate tablets from the United States following the failure of dissolution tests, said the US Food and Drug Administration.

Indian Pharmaceutical Company Recalls Anti-seizure and Hypertension Drugs from US Market
Hyderabad-based Dr Reddy’s Laboratories recalled the drugs as the tablets failed dissolution test and some are close to expiry date.

Dr. Reddy's Laboratories Net Profit Up by 14% in the First Quarter of 2015-16
Total income of the company has increased from Rs. 3,536.02 crore for the quarter ended June 30, 2014 to Rs. 3,770.25 crore for the quarter ended June 30, 2015.